Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

As The Hive Evolves, More Companies Prepare to Join the Program

Posted on December 11th, 2017 by in Pharma R&D

This year, four companies working in early-stage drug development were able to power their efforts with an array of Elsevier tools by participating in The Hive. Now, more promising pharma and biotech start-ups are in the process of entering into The Hive Continue reading “As The Hive Evolves, More Companies Prepare to Join the Program” »

Extreme Makeover: Clinical Trials Edition

Posted on December 4th, 2017 by in Pharma R&D

In a piece featured in the PharmaTimes, Katrina Megget points out the sad state of affairs when it comes to clinical trials, highlighting some appalling stats on the frequent failure to reach enrollment targets (in some cases, not finding any patients at all) and the tendency for studies to go on far longer than anticipated. Continue reading “Extreme Makeover: Clinical Trials Edition” »

As Drug Development Costs Skyrocket, AI Offers Some Hope

Posted on November 20th, 2017 by in Pharma R&D

Last year, researchers from the Tufts Center for the Study of Drug Development published a paper in the Journal of Health Economics that provided an assessment of the current cost for pharmaceutical companies to discover and develop new drugs and biologics. Continue reading “As Drug Development Costs Skyrocket, AI Offers Some Hope” »

Myelo Therapeutics Takes on Unmet Needs in Cancer

Posted on November 17th, 2017 by in Pharma R&D

Many pharmaceutical and biotechnology start-ups have been founded for the purpose of taking on unmet needs. It has often been difficult for the larger, more established pharma companies to focus on these narrower problems, so the leaner, scrappier start-ups are putting their passion and brainpower to the challenges that have yet to be tackled. Continue reading “Myelo Therapeutics Takes on Unmet Needs in Cancer” »

  1. 1
  2. 2
  3. 3
  4. 7